43 peer-reviewed studies on the supplements, nutrition, and lifestyle changes that you can start today to actively prevent your likelihood of developing invasive breast cancer. Click the orange button to the right to get started.
Studies confirm that treatments for DCIS such as lumpectomy, whole-breast radiation and/or an aromatase inhibitor (tamoxifen) will reduce the risk of relapse of DCIS or invasive breast cancer.
Studies also confirm that the conventional therapies mentioned above can cause short, long-term and late stage side effects as well. Further, “Almost all women with DCIS survive over the long term, regardless of whether they get lumpectomies or mastectomies, studies have shown.”
What if patients could choose a therapy to reduce her risk of breast cancer but not risk toxic side effects? Or choose minor treatment such as a lumpectomy but not risk side effects that come from radiation and chemotherapy (tamoxifen is chemotherapy after all)?
Studies have identified a host of non-toxic, non-conventional therapies that reduce the risk of breast cancer. Many of these therapies, such a antioxidant supplementation, also reduce the risk of other cancers.
I am a cancer survivor and cancer coach. I have lived with an “incurable” cancer since my diagnosis in ’94 by living an evidence-based, non-toxic, anti-cancer lifestyle through nutrition, supplementation, bone health, detoxification, etc. I have learned that conventional oncology has little to offer pre-cancers (DCIS) and late stage or incurable cancers.
To learn more about DCIS and the evidence-based therapies that can help you prevent its spread into invasive breast cancer, please watch the video below:
Have you been diagnosed with DCIS? Scroll down the page, post a question or comment and I will reply to you ASAP.
“Barbara Nickles and Ligia Toro de Stefani are both women in their early 60s who were diagnosed with abnormal cells in a breast, or Stage 0 breast cancer, as it’s sometimes labeled. Nickles decided to have a double mastectomy. Toro de Stefani opted for “active surveillance” and a twice-yearly battery of tests…
The two illustrate the vexing questions facing the 60,000 women a year diagnosed in this country with ductal carcinoma in situ (DCIS), a condition in which cancerous-looking cells are found in the breast duct. What exactly is it — a pre-cancer, cancer or more a risk factor? How much treatment is too much? Too little? Which women can safely skip surgery? What about those who want more treatment than their doctors recommend?
The DCIS conundrum is sparking increasingly heated debate among physicians as well. Most say the condition, while not cancer, needs aggressive treatment because 20 percent to 30 percent of cases will spread to surrounding tissue and become invasive cancer if left alone. To date, that has meant surgery for DCIS patients; most have lumpectomies, often followed by radiation, but some undergo mastectomies. Some women also end up taking an anti-cancer drug — such as tamoxifen — for several years…
About 255,200 women will be diagnosed with breast cancer this year, with about 1 in 4 of those with DCIS — a condition that was rarely identified before mammograms became widespread in the 1980s. Almost all women with DCIS survive over the long term, regardless of whether they get lumpectomies or mastectomies, studies have shown…